BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Infographics: Dynamic digital data analysis
BioWorld 2024 review
BioWorld MedTech 2024 review
BioWorld Science 2024 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Israel
Rise of obesity
Radiopharmaceuticals
Biosimilars
Aging
IVDs on the rise
Coronavirus
Artificial intelligence
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Sunday, January 5, 2025
See today's BioWorld
Home
» Backin’ the RSV: Pfizer expands its programs viral programs with Reviral acquisition
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Backin’ the RSV: Pfizer expands its programs viral programs with Reviral acquisition
April 7, 2022
By
Lee Landenberger
No Comments
Pfizer Inc., with pockets bulging from COVID-19 vaccine money, is taking another step in respiratory syncytial virus (RSV) development with its acquisition of Reviral Ltd.
BioWorld
Deals and M&A
Acquisition
